According to the consensus statement, MEN1 is an endocrine tumor syndrome that is found in ... Although pancreatic neuroendocrine tumors are less prevalent, they are associated with a higher ...

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine ...

A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...

A panelist discusses how neuroendocrine tumors are defined by World Health Organization (WHO) classification, graded based on Ki-67 proliferative index, diagnosed through imaging (often incidentally), ...

They share the latest recommendations on managing symptoms related to hormone excess, including carcinoid syndrome and carcinoid heart disease, managing symptoms of functioning pancreatic ...

This syndrome typically appears once neuroendocrine tumors spread—particularly to the liver—releasing hormones into the bloodstream that the body can't filter fast enough. The result? A complex, ...

A new combination therapy that pairs a radiopharmaceutical (177 Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been deemed feasible and tolerable for neuroendocrine cancer patients.

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is a mainstay strategy for low- to intermediate-grade metastatic neuroendocrine tumor patients. While this targeted radiopharmaceutical ...